someone explain FLOW to me like I have not read a paper in years
someone explain FLOW to me like I have not read a paper in years. Searched first, found three threads that contradict each other, hence the post. The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table. Compared myself to a trial mean for about six months…
Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.
Added the trial identifier to the title so this thread is findable in two years.
trial populations get support that nobody on this board gets
trial populations get support that nobody on this board gets
Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.
Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.
STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable
Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.